BridgeBio received early approval to launch its drug, acoramidis, for treating transthyretin amyloid cardiomyopathy. The drug, to be sold as Attruby, will compete with Pfizer's Vyndaqel.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing

BridgeBio received early approval to launch its drug, acoramidis, for treating transthyretin amyloid cardiomyopathy. The drug, to be sold as Attruby, will compete with Pfizer's Vyndaqel.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing